KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Retained Earnings (2016 - 2025)

Neogenomics (NEO) has disclosed Retained Earnings for 16 consecutive years, with $4000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 101.94% year-over-year to $4000.0, compared with a TTM value of $4000.0 through Dec 2025, up 101.94%, and an annual FY2025 reading of $4000.0, up 101.94% over the prior year.
  • Retained Earnings was $4000.0 for Q4 2025 at Neogenomics, up from -$423.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $47.3 million in Q2 2021 and bottomed at -$423.9 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$65.6 million, with a median of -$1.6 million recorded in 2023.
  • The sharpest move saw Retained Earnings surged 287.89% in 2021, then crashed 65829.24% in 2025.
  • Year by year, Retained Earnings stood at -$638000.0 in 2021, then crashed by 511.13% to -$3.9 million in 2022, then tumbled by 6236.37% to -$247.1 million in 2023, then skyrocketed by 99.92% to -$206000.0 in 2024, then skyrocketed by 101.94% to $4000.0 in 2025.
  • Business Quant data shows Retained Earnings for NEO at $4000.0 in Q4 2025, -$423.9 million in Q3 2025, and $29000.0 in Q2 2025.